Budd-Chiari Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.
|
28710306 |
2017 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, a 22 year old female with angiographically proven BCS secondary to JAK2/V617F positive Polycythemia vera on therapeutic warfarin presented with acute liver failure (ALF).
|
26626649 |
2016 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to evaluate the association of factor V Leiden (FVL), Janus kinase 2 (JAK2), prothrombin, and methylene tetrahydrofolate reductase (MTHFR) mutations with primary BCS.
|
26238013 |
2016 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analysis of JAK2 mutation in the patients with idiopathic PVT or BCS showed that 20% had latent MPNs.
|
25698270 |
2015 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
ORPHANET |
Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China.
|
26557140 |
2015 |
Budd-Chiari Syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
|
25698270 |
2015 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
|
23980667 |
2014 |
Budd-Chiari Syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
|
23980667 |
2014 |
Budd-Chiari Syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study.
|
23425079 |
2013 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The incidence and clinical outcomes of JAK2 mutations, novel ten-eleven translocation 2 (TET2) mutations, and the 46/1 haplotype in BCS are unknown for liver transplantation (LT).
|
22467227 |
2012 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.
|
21364191 |
2011 |
Budd-Chiari Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
The presence of JAK2V617F in both ECs and hematopoietic cells belonging to BCS patients with PV indicates that ECs from these patients are involved by the malignant process and that in this subpopulation of patients the disease may originate from a cell common to hematopoietic and endothelial cells.
|
21761323 |
2011 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe a young woman presenting with idiopathic eosinophilia, JAK2 mutation, and BCS.
|
21264914 |
2011 |
Budd-Chiari Syndrome
|
0.700 |
Biomarker
|
disease |
CTD_human |
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.
|
19293426 |
2009 |
Budd-Chiari Syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.
|
19293426 |
2009 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the JAK2-V617F mutation occurs after the onset of monoclonal haematopoiesis; thus the V617F mutation of JAK2 may not be the primary event in the induction of BCS.
|
19308656 |
2009 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Determination of the JAK2 V617F mutation may be useful to recognize patients with Budd-Chiari syndrome with or at risk for the subsequent development of overt myeloproliferative diseases.
|
18600100 |
2008 |
Budd-Chiari Syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
|
18600100 |
2008 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.
|
17849060 |
2007 |
Budd-Chiari Syndrome
|
0.700 |
Biomarker
|
disease |
CTD_human |
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
|
16762626 |
2006 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A clonal mutation in JAK2 tyrosine kinase (JAK2V617F) occurs in a high proportion of patients with MPD and is of use in the characterization of latent MPD in BCS.
|
16762626 |
2006 |
Budd-Chiari Syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
|
16762626 |
2006 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to use JAK2 V617F analysis to re-evaluate the validity of elevated Epo levels as a PV-exclusion criterion in patients with hepatic vein thrombosis [Budd-Chiari syndrome (BCS)].
|
16827884 |
2006 |
Budd-Chiari Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
By resolving the sensitivity bias of the JAK2 mutation with the results of BM histology and clonality assay, CMPD was diagnosed in 53% of patients with EHPVO or BCS.
|
17133457 |
2006 |
Budd-Chiari Syndrome
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|